S&P 500   4,690.25 (+2.15%)
DOW   35,748.77 (+1.48%)
QQQ   398.13 (+3.09%)
AAPL   170.46 (+3.11%)
MSFT   335.25 (+2.78%)
FB   324.10 (+1.96%)
GOOGL   2,944.99 (+2.86%)
AMZN   3,541.46 (+3.33%)
TSLA   1,048.44 (+3.91%)
NVDA   321.88 (+7.16%)
BABA   125.04 (+1.17%)
NIO   33.36 (+3.15%)
CGC   10.85 (+6.90%)
AMD   145.44 (+4.59%)
GE   98.14 (+2.22%)
MU   86.55 (+4.97%)
T   23.12 (-0.69%)
F   19.94 (+3.75%)
DIS   150.53 (+0.11%)
PFE   51.35 (-0.25%)
AMC   31.32 (+8.79%)
ACB   6.44 (+7.87%)
BA   211.43 (+2.70%)
S&P 500   4,690.25 (+2.15%)
DOW   35,748.77 (+1.48%)
QQQ   398.13 (+3.09%)
AAPL   170.46 (+3.11%)
MSFT   335.25 (+2.78%)
FB   324.10 (+1.96%)
GOOGL   2,944.99 (+2.86%)
AMZN   3,541.46 (+3.33%)
TSLA   1,048.44 (+3.91%)
NVDA   321.88 (+7.16%)
BABA   125.04 (+1.17%)
NIO   33.36 (+3.15%)
CGC   10.85 (+6.90%)
AMD   145.44 (+4.59%)
GE   98.14 (+2.22%)
MU   86.55 (+4.97%)
T   23.12 (-0.69%)
F   19.94 (+3.75%)
DIS   150.53 (+0.11%)
PFE   51.35 (-0.25%)
AMC   31.32 (+8.79%)
ACB   6.44 (+7.87%)
BA   211.43 (+2.70%)
S&P 500   4,690.25 (+2.15%)
DOW   35,748.77 (+1.48%)
QQQ   398.13 (+3.09%)
AAPL   170.46 (+3.11%)
MSFT   335.25 (+2.78%)
FB   324.10 (+1.96%)
GOOGL   2,944.99 (+2.86%)
AMZN   3,541.46 (+3.33%)
TSLA   1,048.44 (+3.91%)
NVDA   321.88 (+7.16%)
BABA   125.04 (+1.17%)
NIO   33.36 (+3.15%)
CGC   10.85 (+6.90%)
AMD   145.44 (+4.59%)
GE   98.14 (+2.22%)
MU   86.55 (+4.97%)
T   23.12 (-0.69%)
F   19.94 (+3.75%)
DIS   150.53 (+0.11%)
PFE   51.35 (-0.25%)
AMC   31.32 (+8.79%)
ACB   6.44 (+7.87%)
BA   211.43 (+2.70%)
S&P 500   4,690.25 (+2.15%)
DOW   35,748.77 (+1.48%)
QQQ   398.13 (+3.09%)
AAPL   170.46 (+3.11%)
MSFT   335.25 (+2.78%)
FB   324.10 (+1.96%)
GOOGL   2,944.99 (+2.86%)
AMZN   3,541.46 (+3.33%)
TSLA   1,048.44 (+3.91%)
NVDA   321.88 (+7.16%)
BABA   125.04 (+1.17%)
NIO   33.36 (+3.15%)
CGC   10.85 (+6.90%)
AMD   145.44 (+4.59%)
GE   98.14 (+2.22%)
MU   86.55 (+4.97%)
T   23.12 (-0.69%)
F   19.94 (+3.75%)
DIS   150.53 (+0.11%)
PFE   51.35 (-0.25%)
AMC   31.32 (+8.79%)
ACB   6.44 (+7.87%)
BA   211.43 (+2.70%)
NASDAQ:ENDP

Endo International Stock Forecast, Price & News

$5.24
+0.22 (+4.38%)
(As of 12/7/2021 01:42 PM ET)
Add
Compare
Today's Range
$5.07
$5.33
50-Day Range
$3.24
$6.76
52-Week Range
$1.94
$10.89
Volume
146,070 shs
Average Volume
6.64 million shs
Market Capitalization
$1.22 billion
P/E Ratio
18.71
Dividend Yield
N/A
Beta
1.18
30 days | 90 days | 365 days | Advanced Chart
Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter.


Endo International logo

About Endo International

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment conducts certain manufacturing, quality assurance, R&D and administration functions. The Generic Pharmaceuticals segment conducts certain manufacturing, distribution, quality assurance and administration functions, as well as certain R&D functions. The International Pharmaceuticals segment's operations are currently conducted through Paladin's leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Headlines

Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug
December 2, 2021 |  finance.yahoo.com
Endo International (NASDAQ:ENDP) Issues FY 2021 Earnings Guidance
December 2, 2021 |  americanbankingnews.com
ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study
December 1, 2021 |  finance.yahoo.com
First Week of ENDP July 2022 Options Trading
November 19, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ENDP
CUSIP
29264F20
Employees
3,397
Year Founded
1997

Sales & Book Value

Annual Sales
$2.90 billion
Cash Flow
$5.19 per share
Book Value
($2.95) per share

Profitability

Net Income
$183.94 million
Pretax Margin
-0.24%

Debt

Price-To-Earnings

Miscellaneous

Free Float
227,362,000
Market Cap
$1.22 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

678th out of 1,394 stocks

Pharmaceutical Preparations Industry

319th out of 673 stocks

Analyst Opinion: 2.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Endo International (NASDAQ:ENDP) Frequently Asked Questions

Is Endo International a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Endo International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View analyst ratings for Endo International
or view top-rated stocks.

How has Endo International's stock price been impacted by Coronavirus (COVID-19)?

Endo International's stock was trading at $3.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENDP shares have increased by 34.7% and is now trading at $5.24.
View which stocks have been most impacted by COVID-19
.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Endo International
.

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) announced its earnings results on Thursday, November, 4th. The company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.46 by $0.34. The firm earned $772.03 million during the quarter, compared to analyst estimates of $667.94 million. Endo International had a negative trailing twelve-month return on equity of 108.42% and a net margin of 2.30%. The business's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 earnings per share.
View Endo International's earnings history
.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided EPS guidance of $2.800-$2.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.330. The company issued revenue guidance of $2.90 billion-$2.94 billion, compared to the consensus revenue estimate of $2.79 billion.

What price target have analysts set for ENDP?

6 brokers have issued 12 month target prices for Endo International's stock. Their forecasts range from $3.00 to $11.00. On average, they expect Endo International's stock price to reach $6.60 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price.
View analysts' price targets for Endo International
or view top-rated stocks among Wall Street analysts.

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Blaise A Coleman, President, Chief Executive Officer & Director
  • Robert Polke, Global Head-Operations
  • Mark Bradley, Chief Financial Officer & Executive Vice President
  • Ruth Thorpe, Chief Information Officer
  • Susan Williamson, Chief Compliance Officer & Senior Vice President

What is Paul Campanelli's approval rating as Endo International's CEO?

25 employees have rated Endo International CEO Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among Endo International's employees.

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Who are Endo International's major shareholders?

Endo International's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.65%), LSV Asset Management (1.03%), Bank of New York Mellon Corp (0.93%), Balyasny Asset Management LLC (0.00%), Balyasny Asset Management LLC (0.00%) and Bain Capital Public Equity Management II LLC (0.00%). Company insiders that own Endo International stock include International Plc Endo and Shane Cooke.
View institutional ownership trends for Endo International
.

Which institutional investors are selling Endo International stock?

ENDP stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Geode Capital Management LLC, Marshall Wace LLP, New York State Common Retirement Fund, Tudor Investment Corp Et Al, Hunter Associates Investment Management LLC, O Shaughnessy Asset Management LLC, and Hennion & Walsh Asset Management Inc..
View insider buying and selling activity for Endo International
or view top insider-selling stocks.

Which institutional investors are buying Endo International stock?

ENDP stock was acquired by a variety of institutional investors in the last quarter, including LSV Asset Management, Bain Capital Public Equity Management II LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Citadel Advisors LLC, BNP Paribas Arbitrage SA, Jane Street Group LLC, and Caption Management LLC.
View insider buying and selling activity for Endo International
or or view top insider-buying stocks.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $5.24.

How much money does Endo International make?

Endo International has a market capitalization of $1.22 billion and generates $2.90 billion in revenue each year. The company earns $183.94 million in net income (profit) each year or $0.28 on an earnings per share basis.

How many employees does Endo International have?

Endo International employs 3,397 workers across the globe.

When was Endo International founded?

Endo International was founded in 1997.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

Where are Endo International's headquarters?

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at (531) 268-2000, via email at [email protected], or via fax at 800-329-3636.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.